P. Antoniw

发表

Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma

E. Newlands, K. Bagshawe, C. Brindley, 2004, Cancer Chemotherapy and Pharmacology.

Plasma and tissue disposition of mitozolomide in mice.

E. Newlands, C. Brindley, P. Antoniw, 1986, British Journal of Cancer.

A cytotoxic agent can be generated selectively at cancer sites.

C. Springer, S. Sharma, R. Melton, 1988, British Journal of Cancer.

Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

R. Owens, A. Lawson, R. Owens, 1995, British Journal of Cancer.

ANTIBODY-ENZYME CONJUGATES CAN GENERATE CYTOTOXIC DRUGS FROM INACTIVE PRECURSORS AT TUMOR SITES

K. Bagshawe, R. Sherwood, P. Burke, 1991 .

Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.

R. Sherwood, F. Searle, P. Burke, 1990, British Journal of Cancer.

Improved tumour targeting with recombinant antibody–macrocycle conjugates

T. J. Norman, L. Royle, D. Parker, 1995 .

Antibody directed enzyme prodrug therapy (ADEPT): clinical report.

C. Springer, S. Sharma, K. Bagshawe, 1991, Disease markers.

Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.

C. Springer, S. Sharma, K. Bagshawe, 1991, Disease markers.

Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.

C. Springer, K. Bagshawe, M. Jarman, 1990, Journal of medicinal chemistry.

An in vivo model for screening peptidomimetic inhibitors of gelatinase A.

S. Chander, B. Mason, N. Beeley, 1995, Journal of pharmaceutical sciences.

Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines

E. Newlands, R. Pedley, C. Brindley, 2004, Cancer Chemotherapy and Pharmacology.

Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.

C. Springer, G. T. Rogers, K. Bagshawe, 1991, European journal of cancer.

Prolonged in vivo residence times of antibody fragments associated with albumin.

A. Nesbitt, A. Suitters, A. P. Chapman, 2001, Bioconjugate chemistry.

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).

J. Humm, L. Old, S. Welt, 1996, British Journal of Cancer.

Therapeutic antibody fragments with prolonged in vivo half-lives

Mariangela Spitali, S. Stephens, A. P. Chapman, 1999, Nature Biotechnology.

Selective uptake of toxic nucleoside (125IUdR) by resistant cancer.

K. Bagshawe, R. Pedley, J. Boden, 1991, The British journal of radiology.

acidanditsactive parent druginmice

R. Sherwood, F. Searle, P. Burke, 1990 .

Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.

D. Humphreys, B. Carrington, S. Heywood, 2007, Protein engineering, design & selection : PEDS.

Formatting antibody fragments to mediate specific therapeutic functions.

A. Nesbitt, A. N. Weir, A. P. Chapman, 2002, Biochemical Society transactions.

F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model.

A. Suitters, P. Stephens, D. Humphreys, 1998, Journal of immunological methods.

Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).

C. Springer, K. Bagshawe, C. Springer, 1991, Anti-cancer drug design.

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT) IN HUMAN TUMOR XENOGRAFT MODELS

P. Burke, K. Bagshawe, R. Sherwood, 1990 .